Article

Testosterone Therapy and Cardiovascular Risk

Dr. Abraham Morgentaler, an Associate Clinical Professor of Urology at Harvard Medical School and affiliated with Beth Israel Deaconess Medical Center, in Boston, MA, along with his coauthors, explore and clarify in the February 2015 issue of Mayo Clinic Proceedings, the value of testosterone therapy in men, and in particular the issue of cardiovascular risk.  

Source: YouTube

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Related Content
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
March 14th 2025

What determines the optimal urinary diversion?

Anne K. Schuckman, MD
"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Radioligand therapy shows promising safety in patients with mCRPC
March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke
The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Novel drug delivery approach shows promise for UTI
March 12th 2025

Novel drug delivery approach shows promise for UTI

Hannah Clarke
The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.
House passes bill that includes 57% budget cut to medical research programs
March 12th 2025

House passes bill that includes 57% budget cut to medical research programs

Hannah Clarke
This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis.
© 2025 MJH Life Sciences

All rights reserved.